In high school, Kat Cole was a Hooters girl. She’s now the CEO of a billion-dollar company, AG1. Here, she weighs in on wellness in 2026, Ozempic, and Burning Man.
A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the future of genetic medicine and patient care.
The abrupt revision of the U.S. childhood vaccine schedule from 17 vaccines to 11. belies promises to the American people that access to vaccines would not be affected.
With major NIH cuts under Trump, here are initiatives in states like New York, California and Massachusetts to get state governments to support more scientific research.
Forbes columnist Sachin Jain describes 10 new year’s resolutions to help healthcare leaders to lead better in the year 2026.
Midterm elections and surging healthcare costs are colliding in 2026. Here’s what these pressures may force politicians, insurers and drugmakers to do.
Brian Lian founded publicly traded Viking Therapeutics to focus on metabolic diseases. With obesity drugs in development and the GLP-1 space booming, it’s now a prime M&A target for giants jostling for their share of a potential $100 billion market.
A radiologist and public health expert breaks down what we know about President Trump’s CT scan, and what this means for his health.
Differences in vaccination policies illustrate the importance of context, regarding distinct healthcare systems and the vaccine stance taken by public health officials.
Childhood vaccine schedules among U.S. peers differ marginally. Unlike the U.S., however, peer health officials don’t sow doubt among the public about vaccination.